1
Total investments
1
Early stage
0
Mid stage
0
Late stage
5y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
May 2021
Monolith Management is an investment manager focused on growth companies in public and private markets. We invest in the technology, software, consumer and healthcare sectors using a fundamental, research-driven approach.
The fund was founded by a team of like-minded investors whose experiences span private and public investments
We are looking for great founders, please contact us at bp@monolithmgt.com
Experience · 3 entries
All (3)
Investments (1)
Founder (1)
2021
Investor
May 2021
Monolith Management is an investment manager focused on growth companies in public and private markets. We invest in the technology, software, consumer and healthcare sectors using a fundamental, research-driven approach.
The fund was founded by a team of like-minded investors whose experiences span private and public investments
We are looking for great founders, please contact us at bp@monolithmgt.com
2016
Postdoctoral Research Associate
Dec 2016
The Massachusetts Institute of Technology (MIT) is a private research university located in Cambridge, Massachusetts. MIT is devoted to the advancement of knowledge and education of students in areas that contribute to or prosper in an environment of science and technology.
2014
Co-founder and CTO
Jan 2014
Our Mission. Qlibrium is committed to helping patients live life to the fullest by developing and innovating discreet and flexible drug delivery solutions.
Our Aim. Qlibrium is developing a highly flexible platform technology for delivering injectable drugs into subcutaneous tissue with a wearable on-body delivery system that brings dramatic improvements over existing devices to both users and to pharmaceutical companies.
Who is Qlibrium. Qlibrium, formerly known as Cam Med, began with a simple question: Why can’t a pump for injectable drugs work like an extension of the body? For patients with chronic conditions such as diabetes, Parkinson’s disease, hormone deficiencies, and blood disorders, as well as other conditions that require frequent injections of subcutaneous drugs, a better wearable pump translates into improved compliance and outcomes.
Over the past several years, Qlibrium has been working to bring our vision of marked simplicity to reality with development of the QLib platform for prefilled delivery of drugs and biologics and QForma for diabetes patients. We have been issued several patents, with a strong portfolio of pending patents on key elements of our technology platform.
We have been recognized with prizes from MassChallenge, the Centre for ADVANCEMENT OF SCIENCE IN SPACE, the New England Pediatric Device Consortium, the Massachusetts Medical Device Development Center, and we are a member of JLABS, part of Johnson & Johnson Innovation.
Today, we are working with pharmaceutical partners to deliver a better experience to patients because patient acceptance builds compliance.
